


Update Kardiologie - 1. Juli 2021 Klinik Linde



ESC VHF Guidelines 2020

Was muss die Hausärztin wissen

Dr. med. Martin Rotter
Kardiologische Gemeinschaftspraxis AG
HerZentrum Bern
3013 Bern



Kardiologische Gemeinschaftspraxis
persönlich · erfahren · engagiert

Take home message...

- Diagnose
- Therapieoptionen
 - Antikoagulation
 - Medikamentös
 - Interventionell
 - Substrat
- Prognose


Fallbeispiel Diagnose

- 47 jährige Patientin, intermittierende Palpitationen, 2 x Synkope
- Echo / Ergo unauffällig
- AnfallsEKG mit Vorhofflimmern -> Ablation
- 8 Jahre später rezidivierende Palpitationen ohne Synkopen, arrhythmisch



Kardiologische Gemeinschaftspraxis
persönlich · erfahren · engagiert

Fallbeispiel Diagnose



Fallbeispiel Diagnose

- Patientin in der Zwischenzeit 58 jährig,
behandelte art. Hypertonie
- CHADS Vasc 2 -> OAK?
- Vd. ad VHF genügt nicht
- Wie weiter?


Geburtsdatum: 29.06.1962 (Alter 58)

Aufgezeichnet am 02.06.2021 um 08:21

Vorhofflimmern — ❤️ 146 BPM ☺

Dieses EKG deutet auf Vorhofflimmern und eine hohe Herzfrequenz hin.

Wenn du dieses Ergebnis nicht erwartest hast oder deine Herzfrequenz hoch bleibt, solltest du bald mit deinem Arzt sprechen.



25 mm/s, 10 mm/mV, Ableitung I, 512 Hz, iOS 14.6, watchOS 7.5, WatchOS 1, Algorithmus Version 2 – Die Wellenform ist vergleichbar mit einem Ableitung-I-EKG. Weitere Informationen sind in der Gebrauchsanweisung erhältlich.

ORIGINAL ARTICLE

Large-Scale Assessment of a Smartwatch to Identify Atrial Fibrillation

Marco V. Perez, M.D., Kenneth W. Mahaffey, M.D., Haley Hedlin, Ph.D.,
John S. Rumsfeld, M.D., Ph.D., Ariadna Garcia, M.S., Todd Ferris, M.D.,
Vidhya Balasubramanian, M.S., Andrea M. Russo, M.D., Amol Rajmane, M.D.,
Lauren Cheung, M.D., Grace Hung, M.S., Justin Lee, M.P.H., Peter Kowey, M.D.,
Nisha Talati, M.B.A., Divya Nag, Santosh E. Gummidipundi, M.S.,
Alexis Beatty, M.D., M.A.S., Mellanie True Hills, B.S., Sumbul Desai, M.D.,
Christopher B. Granger, M.D., Manisha Desai, Ph.D., and
Mintu P. Turakhia, M.D., M.A.S., for the Apple Heart Study Investigators*

RESULTS

We recruited 419,297 participants over 8 months. Over a median of 117 days of monitoring, 2161 participants (0.52%) received notifications of irregular pulse. Among the 450 participants who returned ECG patches containing data that could be analyzed — which had been applied, on average, 13 days after notification — atrial fibrillation was present in 34% (97.5% confidence interval [CI], 29 to 39) overall and in 35% (97.5% CI, 27 to 43) of participants 65 years of age or older. Among participants who





Kardiologische Gemeinschaftspraxis
persönlich · erfahren · engagiert

Sinusrhythmus — ❤ 53 BPM ♂

Dieses EKG weist keine Anzeichen von
Vorhofflimmern auf.




50 mm/s, 10 mm/mV, Ableitung I, III, aVL, aVF, V3, V5, V6, V1, V2, V3R, V4R, V5R, V6R — Die Reihenfolge ist vergleichbar mit einem Ablesungstrichter. Weitere Informationen sind in der
Dokumentation enthalten.



Kardiologische Gemeinschaftspraxis
persönlich · erfahren · engagiert

Atrial Fibrillation — ❤️ 118 BPM Average

This ECG shows signs of AFib.
If this is an unexpected result, you should talk to your doctor.




Diagnose -> Definition

Definition	
AF	<p>A supraventricular tachyarrhythmia with uncoordinated atrial electrical activation and consequently ineffective atrial contraction.</p> <p>Electrocardiographic characteristics of AF include:</p> <ul style="list-style-type: none"> • Irregularly irregular R-R intervals (when atrioventricular conduction is not impaired), • Absence of distinct repeating P waves, and • Irregular atrial activations.

Diagnose & Screening

Recommendations for diagnosis of AF	ECG documentation is required to establish the diagnosis of AF. A standard 12-lead ECG recording or a single-lead ECG tracing of ≥ 30 s showing heart rhythm with no discernible repeating P waves and irregular RR intervals (when atrioventricular conduction is not impaired) is diagnostic of clinical AF.	I
Recommendations for structured characterization of AF	Structured characterization of AF, which includes clinical assessment of stroke risk, symptom status, burden of AF, and evaluation of substrate, should be considered in all AF patients, to streamline the assessment of AF patients at different healthcare levels, inform treatment decision making, and facilitate optimal management of AF patients.	IIa
Recommendations for screening to detect AF	When screening for AF it is recommended that: <ul style="list-style-type: none"> • The individuals undergoing screening are informed about the significance and treatment implications of detecting AF. • A structured referral platform is organized for screen-positive cases for further physician-led clinical evaluation to confirm the diagnosis of AF and provide optimal management of patients with confirmed AF. • Definite diagnosis of AF in screen-positive cases is established only after the physician reviews the single-lead ECG recording of ≥ 30 s or 12-lead ECG and confirms that it shows AF. 	I



Paroxysmale Rhythmusstörungen

- Anfallsweise
- Im Intervall oft alles normal
- Anfalls - EKG für Diagnostik und Therapie unerlässlich
- Lange Attacken -> 12 Kanal EKG
- Kurze Attacken?

Screening

	Sensitivity	Specificity
Pulse taking ²⁰³	87 - 97%	70 - 81%
Automated BP monitors ^{204 – 207}	93 - 100%	86 - 92%
Single lead ECG ^{208 – 211}	94 - 98%	76 - 95%
Smartphone apps ^{188,189,191,195,212,213}	91.5 - 98.5%	91.4 - 100%
Watches ^{196,198,213,214}	97 - 99%	83 - 94%

AF SCREENING

RISKS

- Abnormal results may cause anxiety
- ECG misinterpretation results may lead to overdiagnosis and overtreatment
- ECG may detect other abnormalities (true or false positives) that may lead to invasive tests and treatments that have the potential for serious harm (e.g., angiography / revascularisation with bleeding, contrast-induced nephropathy and allergic reactions to the contrast)

BENEFITS

Prevention of:

- Stroke/SE using OAC in patients at risk
- Subsequent onset of symptoms

Prevention/reversal of:

- Electrical/mechanical atrial remodelling
- AF-related haemodynamic derangements
- Atrial and ventricular tachycardia-induced cardiomyopathy

Prevention/reduction of:

- AF-related morbidity; hospitalization; mortality

Reduction of:

- The outcomes associated with conditions / diseases associated with AF that are discovered and treated as a consequence of the examinations prompted by AF detection

Screening nach cerebrovaskulärem Insult

Recommendations	Class ^a	Level ^b
In patients with acute ischaemic stroke or TIA and without previously known AF, monitoring for AF is recommended using a short-term ECG recording for at least the first 24 h, followed by continuous ECG monitoring for at least 72 h whenever possible. ^{1113–1116}	I	B
In selected ^c stroke patients without previously known AF, additional ECG monitoring using long-term non-invasive ECG monitors or insertable cardiac monitors should be considered, to detect AF. ¹¹¹²	IIa	B




Kardiologische Gemeinschaftspraxis
persönlich · erfahren · engagiert

Smartphone Apps

The screenshot shows the iPad home screen with several app icons. The 'Photo AFib Detector' app icon is highlighted. The app's main screen is displayed, featuring a large blue heart with the letters 'AF' inside. Below the heart are four yellow stars and the text 'Zu wenig Wirkungspotenz'. The price 'CHF 2.00' is shown in a blue box. The app interface includes sections for 'Photo AFib Detector', 'Help', 'Information', 'Statistics', 'History', and 'Reference Information'. A detailed description of the app's features and usage is provided in the 'Information' section.


The screenshot shows the App Store page for the 'Instant Herzfrequenz' app. At the top, there's a large circular icon with a heart rate of 85 bpm. Below it is the app's name 'Instant Herzfrequenz' and the subtitle 'Puls Messen & Herzschlag'. A blue cloud-like icon indicates it's a free app. The rating is 4.6 stars from 694 reviews. A 'Neue Funktionen' section lists a bug fix. On the right, a 'Versionsverlauf' section shows 'Vor 2 W.' and 'Version 5.160'. The 'Vorschau' section displays four screenshots of the app's interface: 1. 'DIE GENAUSTE HERZFREQUENZ-APP' showing a large circular meter with 108 bpm. 2. 'ÜBERPRÜFEN SIE SOFORT IHR STRESSNIVEAU' showing a similar circular meter with 85 bpm. 3. 'SCHNELL UND EINFACH ZU BEMEREN' showing a hand pointing to a finger position sensor. 4. 'PROFESSIONELLE BERICHTE FÜR IHREN ARZT' showing a detailed report with a heart rate of 149 bpm. Below the screenshots, it says 'iPhone'. To the right, 'Azumio Inc.' is listed as the developer. The bottom section shows a summary of reviews: a large '4,6' rating, 'von 5', '694 Wertungen', and a row of five small icons for filters: 'Heute', 'Spiele', 'Apps', 'Updates', and 'Suchen'.



Case report

- 58 jähriger Patient, neu NYHA II
- Belastungstest: 2:1 AV block unter Belastung
- Pulmonale Sarkoidose bekannt
- Echo und kardiales MRI normal
- Keine kardiovaskulären Risikofaktoren
- Procedere: 2-Kammer Schrittmacherimplantation


AHRE - atrial high rate episodes im Schrittmacher



CHA₂DS₂-Vasc Score 0, asymptomatic -> wie weiter?

Case report

- Im Verlauf TIA (CHA₂DS₂-Vasc -> 2)
- In PM Abfrage vermehrt AHRE
- Beginn Antikoagulation?



Antikoagulation

Recommendations	Class ^a	Level ^b
For stroke prevention in AF patients who are eligible for OAC, NOACs are recommended in preference to VKAs (excluding patients with mechanical heart valves or moderate-to-severe mitral stenosis). ^{423,424}	I	A
For stroke risk assessment, a risk-factor-based approach is recommended, using the CHA ₂ DS ₂ -VASc clinical stroke risk score to initially identify patients at 'low stroke risk' (CHA ₂ DS ₂ -VASc score = 0 in men, or 1 in women) who should not be offered antithrombotic therapy. ^{334,388}	I	A
OAC is recommended for stroke prevention in AF patients with CHA ₂ DS ₂ -VASc score ≥ 2 in men or ≥ 3 in women. ⁴¹²	I	A
OAC should be considered for stroke prevention in AF patients with a CHA ₂ DS ₂ -VASc score of 1 in men or 2 in women. Treatment should be individualized based on net clinical benefit and consideration of patient values and preferences. ^{338,378,380}	IIa	B
Antiplatelet therapy alone (monotherapy or aspirin in combination with clopidogrel) is not recommended for stroke prevention in AF. ^{440,441,480,481}	III	A

Antikoagulation: ja

- LAA Verschluss: bedingt...

Recommendations for occlusion or exclusion of the LAA	IIb	B
LAA occlusion may be considered for stroke prevention in patients with AF and contraindications for long-term anticoagulant treatment (e.g. intracranial bleeding without a reversible cause). ^{448,449,481,482}		
Surgical occlusion or exclusion of the LAA may be considered for stroke prevention in patients with AF undergoing cardiac surgery. ^{459,483}	IIb	C

Neue Guidelines - was muss ich wissen?

Diagnose


-> weil wichtigste Komplikation CVI

Antikoagulation

-> weil effektivste Massnahme zur Verhinderung des CVI

Therapieoptionen

-> Multidisziplinär



Kardiologische Gemeinschaftspraxis
persönlich · erfahren · engagiert

Therapieoptionen

- A**ntikoagulation
 - CHA₂DS₂-Vasc
 - DOAC
- B**essere Symptomkontrolle
 - Optimale Frequenzkontrolle
 - Rhythmuskontrolle
- C**omorbiditäten
 - Hypertonie
 - Gewicht
 - Sport
 - Alkohol

Therapieoptionen

Changes in the recommendations

Recommendations about integrated AF management

2020

Class^a

2016

Class^a

AF catheter ablation after drug therapy failure

AF catheter ablation for PVI is recommended for rhythm control after one failed or intolerant class I or III AAD, to improve symptoms of AF recurrences in patients with:

- Paroxysmal AF, or
- Persistent AF without major risk factors for AF recurrence, or
- Persistent AF with major risk factors for AF recurrence.

I

Catheter or surgical ablation should be considered in patients with symptomatic persistent or long-standing persistent AF refractory to AAD therapy to improve symptoms, considering patient choice, benefit and risk, supported by an AF Heart Team.

IIa

First-line therapy

AF catheter ablation:

- Is recommended to reverse LV dysfunction in AF patients when tachycardia-induced cardiomyopathy is highly probable, independent of their symptom status.
- Should be considered in selected AF patients with HFrEF to improve survival and reduce HF hospitalization.

I

AF ablation should be considered in symptomatic patients with AF and HFrEF to improve symptoms and cardiac function when tachycardia-induced cardiomyopathy is suspected.

IIa

Therapieoptionen

Changes in the recommendations

Recommendations about integrated AF management

2020

Class^a 2016

Class^a

Techniques and technologies

Complete electrical isolation of the pulmonary veins is recommended during all AF catheter-ablation procedures.

I

Catheter ablation should target isolation of the pulmonary veins using radiofrequency ablation or cryotherapy balloon catheters.

IIa

If patient has a history of CTI-dependent atrial flutter or if typical atrial flutter is induced at the time of AF ablation, delivery of a CTI lesion may be considered.

IIb

Ablation of common atrial flutter should be considered to prevent recurrent flutter as part of an AF ablation procedure if documented or occurring during the AF ablation

IIa

Lifestyle modification and other strategies to improve outcomes of ablation

Weight loss is recommended in obese patients with AF, particularly those who are being evaluated to undergo AF ablation.

I

In obese patients with AF, weight loss together with management of other risk factors should be considered to reduce AF burden and symptoms.

IIa


Therapieoptionen


- 57 jähriger Patient, seit 6 Jahren intermittierendes VHF, hochsymptomatisch
- Echo und Ergo normal, Ruhe EKG normal, Anfalls EKG -> tc VHF
- Seit anfangs 2021 vermehrt prolongierte Episoden (bis 6h, bis 2xWoche)
- CHA₂DS₂-Vasc Score 0, EHRA Score IIb
- Wie weiter?
 1. Frequenzkontrolle vs. Rhythmuskontrolle
 2. Wenn Rhythmuskontrolle: Medikamente vs. Ablation
 3. Antikoagulation?


Therapieoptionen

- „Junger“ gesunder Patient, normal strukturiertes Herz
- Sportlich, will keine Medikamente

First-line therapy			
AF catheter ablation for PVI should/may be considered as first-line rhythm control therapy to improve symptoms in selected patients with symptomatic:			
<ul style="list-style-type: none"> Paroxysmal AF episodes, 240–242,614,615 or Persistent AF without major risk factors for AF recurrence, 253–255,364,598–601,609,610,633,636,641,724,745,746,832 	IIa	B	
as an alternative to AAD class I or III, considering patient choice, benefit, and risk.	IIIb	C	
AF catheter ablation:			
<ul style="list-style-type: none"> Is recommended to reverse LV dysfunction in AF patients when tachycardia-induced cardiomyopathy is highly probable, independent of their symptom status, 666,675,676 Should be considered in selected AF patients with HF with reduced LVEF to improve survival and reduce HF hospitalization, 612,659,662–666,668–671,817–826 	I	B	
AF catheter ablation for PVI should be considered as a strategy to avoid pacemaker implantation in patients with AF-related bradycardia or symptomatic pre-automaticity pause after AF conversion considering the clinical situation, 816–818	IIa	B	
	IIa	C	








Therapieoptionen - first line Katheterablation


- Hohe Erfolgsquoten
-> Beste „Symptomkontrolle“ aller verfügbaren Therapien
- Routineeingriff
Einstündiger Eingriff, 1 Nacht hospitalisiert, Komplikationen < 1%
- Über 5 Jahre günstigste Therapieoption
- Zukunft:
Reduktion der Morbidität und Mortalität bei frühem Therapiebeginn
(EAST-AFNET 4 Trial, NEJM 2020)

Therapieoptionen -> ABC -> C -> Comorbidities

European Heart Journal (2020) 42, 373-498




Gewicht und VHF - Mehr = mehr



LEGACY, Sanders et al., J Am Coll Cardiol 2015


Take home message



European Heart Journal (2020) 42, 373-498



European Heart Journal (2020) 42, 373-498



European Heart Journal (2020) 42, 373-498

